Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation
- PMID: 21696568
- DOI: 10.1111/j.1754-9485.2011.02274.x
Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation
Abstract
Introduction: The management of malignant pleural mesothelioma represents one of the most challenging issues in oncology, as there is no proven long-term benefit from surgery, radiotherapy or chemotherapy alone or in combination. Locoregional progression remains the major cause of death, but radical surgical resection may produce major postoperative morbidity. While radical or postoperative radiotherapy using conventional techniques has resulted in severe toxicity with no impact on survival, recent advances in radiotherapy delivery may be more effective.
Methods: We treated patients with locally advanced mesothelioma whose tumours had been sub optimally resected with high-dose three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) to large volumes of one hemithorax, using CT and positron emission tomography (PET) scan-based treatment planning. Clinical outcomes were assessed by determining patterns of failure and metabolic changes in total glycolytic volume (TGV) between pre- and post-irradiation( 18) F-FDG PET/CT scans and by recording acute and late toxicity grades.
Results: Fourteen patients were analysed with 40 PET scans performed before and up to 4.5years after radiotherapy. Eleven patients had pleurectomy/decortications, one had an extrapleural pneumonectomy and two had no surgery. Four patients who received chemotherapy had all progressed prior to radiotherapy. After radiotherapy, the in-field local control rate was 71%. No progression occurred in two patients, one was salvaged with further radiotherapy to a new site, four recurred inside the irradiated volume all with concurrent distant metastases and the other seven had distant metastases only. The TGVs were reduced by an average of 67% (range 12-100%) after doses of 45 to 60Gy to part or all of one hemithorax. There were no serious treatment-related toxicities. Median survival was 25months from diagnosis and 17months after starting radiotherapy.
Conclusions: We have established that mesothelioma can be locally controlled with high radiation doses using 3DCRT or IMRT, and that strict normal tissue dose constraints have limited radiation toxicities. Radiotherapy should be considered to prevent or delay the local manifestations of progressive disease in suitable patients after surgery including extrapleural pneumonectomy and pleurectomy/decortication. Higher radiation doses may allow more effective palliation.
© 2011 The Authors. Journal of Medical Imaging and Radiation Oncology © 2011 The Royal Australian and New Zealand College of Radiologists.
Similar articles
-
Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.J Thorac Oncol. 2010 Mar;5(3):385-8. doi: 10.1097/JTO.0b013e3181cbf465. J Thorac Oncol. 2010. PMID: 20087231
-
Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.Nucl Med Commun. 2013 Nov;34(11):1075-83. doi: 10.1097/MNM.0b013e3283653862. Nucl Med Commun. 2013. PMID: 23963351
-
Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.Clin Lung Cancer. 2019 Jan;20(1):e29-e38. doi: 10.1016/j.cllc.2018.08.019. Epub 2018 Sep 3. Clin Lung Cancer. 2019. PMID: 30253920
-
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?Interact Cardiovasc Thorac Surg. 2011 May;12(5):806-11. doi: 10.1510/icvts.2010.255901. Epub 2011 Jan 25. Interact Cardiovasc Thorac Surg. 2011. PMID: 21266493 Review.
-
Radiotherapy for the treatment of malignant pleural mesothelioma.Lancet Oncol. 2017 Sep;18(9):e532-e542. doi: 10.1016/S1470-2045(17)30459-X. Lancet Oncol. 2017. PMID: 28884702 Review.
Cited by
-
Computed tomography features of local pleural recurrence in patients with malignant pleural mesothelioma treated with intensity-modulated pleural radiation therapy.Eur Radiol. 2019 Jul;29(7):3696-3704. doi: 10.1007/s00330-018-5937-6. Epub 2019 Jan 28. Eur Radiol. 2019. PMID: 30689034 Free PMC article.
-
Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive.Front Oncol. 2014 Jan 10;3:330. doi: 10.3389/fonc.2013.00330. eCollection 2014 Jan 10. Front Oncol. 2014. PMID: 24455488 Free PMC article. Review.
-
Local and systemic therapies for malignant pleural mesothelioma.Curr Treat Options Oncol. 2014 Dec;15(4):683-99. doi: 10.1007/s11864-014-0314-4. Curr Treat Options Oncol. 2014. PMID: 25266654 Review.
-
Advances in radiation therapy for thoracic malignancies.J Thorac Dis. 2018 Aug;10(Suppl 21):S2431-S2436. doi: 10.21037/jtd.2018.08.10. J Thorac Dis. 2018. PMID: 30206489 Free PMC article. No abstract available.
-
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.J Thorac Dis. 2013 Dec;5(6):E254-307. doi: 10.3978/j.issn.2072-1439.2013.11.28. J Thorac Dis. 2013. PMID: 24416529 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical